Back to Browse Journals » International Journal of Nephrology and Renovascular Disease » Volume 1

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs

Authors James B Wetmore, L Darryl Quarles

Published 13 November 2008 Volume 2008:1 Pages 5—17


Review by Single-blind

Peer reviewer comments 7

James B Wetmore1, L Darryl Quarles1,2

1Department of Medicine, Division of Nephrology, University of Kansas Medical Center, Kansas City, KS, USA; 2The Kidney Institute, University of Kansas Medical Center, Kansas City, KS, USA

Abstract: There is a growing understanding of the pathophysiology of secondary hyperparathyroidism (SHPT) and a recent emergence of new agents for SHPT treatment in patients with advanced kidney disease. At the same time, appreciation that mineral metabolic derangements promote vascular calcification and contribute to excess mortality, along with recognition of potentially important “non-classical” actions of vitamin D, have prompted the nephrology community to reexamine the use of various SHPT treatments, such as activated vitamin D sterols, phosphate binders, and calcimimetics. In this review, the evidence for treatment of SHPT with calcimimetics and vitamin D analogs is evaluated, with particular consideration given to recent clinical trials that have reported encouraging findings with cinacalcet use. Additionally, several controversies in the pathogenesis and treatment of SHPT are explored. The proposition that calcitriol deficiency is a true pathological state is challenged, the relative importance of the vitamin D receptor and the calcium sensing receptor in parathyroid gland function is summarized, and the potential relevance of non-classical actions of vitamin D for patients with advanced renal disease is examined. Taken collectively, the balance of evidence now supports a treatment paradigm in which calcimimetics are the most appropriate primary treatment for SHPT in the majority of end stage renal disease patients, but which nevertheless acknowledges an important role for modest doses of activated vitamin D sterols.

Keywords: secondary hyperparathyroidism, vitamin D, vitamin D receptor, calcium sensing receptor, calcimimetics, kidney disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Treatment of port wine stains with pulsed dye laser: a retrospective study of 848 cases in Shandong Province, People’s Republic of China

Shi W, Wang J, Lin Y, Geng J, Wang H, Gong Y, Liu H, Zhang F

Drug Design, Development and Therapy 2014, 8:2531-2538

Published Date: 12 December 2014

Dissociative symptoms reflect levels of tumor necrosis factor alpha in patients with unipolar depression

Bizik G, Bob P, Raboch J, Pavlat J, Uhrova J, Benakova H, Zima T

Neuropsychiatric Disease and Treatment 2014, 10:675-679

Published Date: 25 April 2014

Paclitaxel: new uses for an old drug

Zhang D, Yang R, Wang S, Dong Z

Drug Design, Development and Therapy 2014, 8:279-284

Published Date: 20 February 2014

Spanish translation, cross-cultural adaptation, and validation of the Questionnaire for Diabetes-Related Foot Disease (Q-DFD)

Castillo-Tandazo W, Flores-Fortty A, Feraud L, Tettamanti D

Vascular Health and Risk Management 2013, 9:501-508

Published Date: 28 August 2013

Nodal involvement pattern in resectable lung cancer according to tumor location

Saeteng S, Tantraworasin A, Euathrongchit J, Lertprasertsuke N, Wannasopha Y

Cancer Management and Research 2012, 4:151-158

Published Date: 7 June 2012

Solid lipid nanoparticle suspension enhanced the therapeutic efficacy of praziquantel against tapeworm

Xie S, Pan B, Shi B, Zhang Z, Zhang X, Wang M, Zhou W

International Journal of Nanomedicine 2011, 6:2367-2374

Published Date: 18 October 2011

Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer

Jeong YI, Kim DH, Chung CW, Yoo JJ, Choi KH, Kim CH, Ha SH, Kang DH

International Journal of Nanomedicine 2011, 6:1415-1427

Published Date: 6 July 2011


RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010

Argatroban in the management of heparin-induced thrombocytopenia

Luciano Babuin, Vittorio Pengo

Vascular Health and Risk Management 2010, 6:813-819

Published Date: 1 September 2010

Ambrisentan for the treatment of pulmonary arterial hypertension

Brian Casserly, James R Klinger

Drug Design, Development and Therapy 2008, 2:265-280

Published Date: 4 December 2008